FTISADTSK is an endogenous stable signature peptide derived from Trastuzumab, which can be accurately assessed using selected reaction monitoring (SRM).
FTISADTSK acetate is a stable endogenous signature peptide sourced from Trastuzumab, which can be monitored using selected reaction monitoring (SRM)[1].